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Although abdominal bloating is one of the most bothersome symptoms experienced by patients
with functional dyspepsia (FD), therapeutic drugs to relieve abdominal bloating have not been
established. We investigated the Kampo (Chinese herbal) medicine, Hangekobokuto (Banxia-
houpo-tang, HKT) for patients with FD from the standpoint of bowel gas retention. The bowel
gas volume calculated from a plain abdominal radiogram (gas volume score, GVS) in FD
patients was significantly higher than that in healthy subjects. Two week administration of
HKT in the FD patients showed a significant decrease of GVS. Furthermore, gastrointestinal
symptoms, especially symptoms of abdominal pain, indigestion and constipation, all of which
are closely related to abdominal bloating, improved significantly in FD patients after the
administration of HKT. These results suggest that HKT improves abdominal bloating
accompanied by the reduction of bowel gas in FD patients.
Keywords: abdominal bloating – aerophagia – functional dyspepsia – functional gastrointestinal
disorders – herbal medicine – prokinetics
Introduction
Functional dyspepsia (FD) is one of the most common
diseases in advanced countries (1–3). Among the various
gastrointestinal symptoms FD causes (4–6), abdominal
bloating is one of the most bothersome. Several factors,
such as bowel gas retention and abnormal sensitivity of
the intestinal wall, are considered to play a role in
making patients experience the sensation of abdominal
bloating (7). However, the exact pathogenesis is still not
clear, and therapeutic drugs to relieve the complaint have
thus not yet been established.
To date, many Kampo medicines have shown efficacy
for the relief of symptoms in dyspeptic patients (8).
Rikkunshito was proved to be effective against FD by
double-blind RCT for the first time. In an earlier study,
we reported that Hangekobokuto (Banxia-houpo-tang,
HKT) increased the gastric emptying rate in FD
patients, and that gastrointestinal symptoms improved
significantly, suggesting that HKT acts as a prokinetic
agent (9).
We investigated HKT for patients with FD from the
standpoint of bowel gas retention, because HKT is
classically considered one of the representative formula-
tions to improve abdominal bloating, which includes an
excess of abdominal gas in its pathophysiology.
Methods
Subjects
Twenty asymptomatic healthy volunteers [all men, mean
age35.4years(26–49)]and30patientswithFD[12menand
18 women, mean age 54.5 years (25–85)] were enrolled.
For reprints and all correspondence: Tetsuro Oikawa, Oriental
Medicine Research Center of the Kitasato Institute, 5-9-1 Shirokane,
Minato-ku, Tokyo 108-8642, Japan. Tel: 03-3444-6161(ext. 4667);
Fax: 03-3445-8448; E-mail: oikawa-t@kitasato.or.jp
 2007 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original worki s
properly cited.HKT was evaluated for bowel gas in 20 healthy volunteers
and 19 [6 men and 13 women, mean age 50.2 years (25–85)]
of the 30 FD patients. The diagnosis of FD was determined
on the basis of international criteria (6). All the FD patients
were classified as ‘post-prandial distress syndrome’. None
of the participants used medication that could affect
gastrointestinal motility for over 2 weeks before the
examinations. All participants provided informed consent
before participating in this study.
Preparation of HKT
HKT is composed of the five drugs shown in Table 1. We
used freeze-dried extracts of HKT, TJ-16 (Tsumura Co.,
Tokyo, Japan) and the three-dimensional HPLC profile
of the methanol solution of TJ-16 described previously
(7). The daily dose for adults is 7.5g, and was
administered orally three times a day before each meal.
Study Protocol
We administered HKT to patients with FD, as well as to
healthy subjects for 2 weeks. Before and after this
administration, we evaluated bowel gas volume calculated
from a plain abdominal radiogram (10). Briefly, plain
abdominal radiographs in the supine position taken in
the fasting state in the morning were digitized and
transmitted to the computer. After the region of bowel
gas was identified, its outline was traced on the monitor.
The total area for the region of bowel gas (gas in
stomach was excluded) was determined as the pixel value
on images by using Scion Image Beta version 4.02. The
ratio of the quantity of bowel gas to the pixel value in
the region surrounded by a horizontal line tangential to
the suprasymphysary margin, a horizontal line tangential
to the uppermost diaphragm and the most lateral line
tangential to the right and left costal arches was defined
as GVS. We also assessed the gastrointestinal symptoms
of the FD patients using the gastrointestinal symptom
rating scale (GSRS) as a questionnaire (11). Our protocol
was approved by the ethical committee in Oriental
Medicine Research Center of the Kitasato Institute.
Statistical Analysis
Data were expressed as meanSE. The statistical sig-
nificance of the differences between measurements made
before and after the administration of HKT was assessed
using the Wilcoxon signed rank test, and differences
between the two groups were assessed using the
Mann–Whitney U-test. A P-value <0.05 was regarded as
significant.
Results
HKT Decreases GVS in FD Patients but not in Healthy
Subjects
The GVS in FD patients (0.0500.006) was signif-
icantly higher than that in the healthy subjects
(0.0260.004) (Fig. 1). The GVS in FD patients showed
a significant decrease (0.0270.005) after 2 weeks of
medication with HKT. In contrast, there was no significant
change (0.0240.003) in the GVS of the healthy volunteers
(Fig. 2).
HKT Improves Gastrointestinal Symptoms in FD Patients
The gastrointestinal symptoms of FD patients as
expressed by the GSRS total score showed significant
improvement after HKT treatment (from 2.480.14 to
2.080.11, P=0.0019). The GSRS symptom scores for
five categories except diarrhea also showed a significant
decrease, especially in the score for indigestion with high
positivity (Table 2).
Discussion
We demonstrated that the Kampo medicine HKT reduces
bowel gas and improves gastrointestinal symptoms in FD
patients. Koide et al. (10) reported that patients with
irritable bowel syndrome (IBS) showed significantly
Table 1. Constituents of Hangekobokuto
Pinelliae tuber 6 g
Hoelen 5g
Magnoliae cortex 3g
Perillae herba 2g
Zingiberis rhizoma 1g
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Figure 1. Comparison of gas volume score (GVS) between healthy
volunteers and patients with functional dyspepsia (FD).
376 Hangekobokuto reduces bowel gas in dyspeptic patientshigher GVS than normal volunteers. Even though, our
controls were younger and all were male, the mean GVS
of healthy volunteers was approximately equal to that of
their original report. They also reported that GVS did
not have an apparent correlation with the total colonic
transit time, an index for colonic peristalsis. Therefore,
GVS is considered a new marker of bowel function in
humans. It is interesting that our data on GVS in patients
with FD fell just between that of patients with IBS and
the data on normal volunteers. Gastroenterologists
currently argue that FD and IBS cannot be completely
distinguished. In addition, a broader definition of
functional gastrointestinal disorders has been proposed
which includes these two disease entities (5). Common
overlap between dyspeptic symptoms and IBS is also
noticed in the Rome III criteria (6). Our data might
reflect the common backgrounds of both FD and IBS.
From this viewpoint, we now intend to investigate the
possibilities of HKT for patients with IBS.
In a former investigation, we demonstrated that HKT
improves gastric motility by measuring the gastric
emptying rate using an ultrasonographic method (9).
Several other reports also support prokinetic action in
ingredients of HKT by animal experiments (12–14).
Therefore, we consider it possible that prokinetic action
might also work in the lower gastrointestinal tract.
The anxiolytic effect of HKT in reducing bowel gas
should also be considered. Magnoliae Cortex contains
honokiol, which was reported to show an anxiolytic effect
in animal experiments (15,16). Pinelliae Tuber is also
reported to have an anxiolytic effect (12). Many of the
patients with FD are considered to also suffer from
anxiety, depression and autonomic nerve disturbance
(17–19), which sometimes lead to the development of
aerophagia due to psychological stress. HKT might
attenuate mental stress and protect FD patients from
aerophagia. The fact that there was no apparent change
of GVS in healthy subjects may provide support for our
hypothesis.
With regard to the subjective symptoms of FD patients,
their gastrointestinal symptoms significantly improved
after the administration of HKT, suggesting that HKT
could be used as an agent for FD. It is noteworthy that
the analysis of individual symptoms showed that indiges-
tion markedly improved out of five individual symptoms
categories. As mentioned before, HKT has often been
prescribed for patients complaining of abdominal bloat-
ing or who show abdominal gas retention by physical
examination. Thus these results are not surprising
because complaints of abdominal bloating would be
most related to this symptom category. In addition, these
results help support the proposal that HKT is effective
for this troublesome complaint in dyspeptic patients.
Finally, we were able to demonstrate the clinical
efficacy of HKT to improve the gastrointestinal symp-
toms of patients with FD. The reduction of bowel gas
may be a characteristic mechanism of action for HKT,
making HKT a possible candidate for a therapeutic drug
for FD, especially for patients with abdominal bloating.
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